Emergent Biosolutions will develop an intranasal treatment for the effects of cyanide poisoning in partnership with the Biomedical Advanced Research and Development Authority at HHS.
The agreement comes amid concerns that cyanide could be used as a chemical weapon. Emergent will develop an intranasal, stabilized form of isoamyl nitrite under the 17-month, $12.7 million agreement.
The project is part of the authority’s work to develop measures to protect against potential terrorist attacks. Emergent will conduct nonclinical and clinical safety and efficacy studies in partnership with BARDA.